Revelation Biosciences Reports $3.3 Million Net Loss in Q2 2026, Increases Operating Expenses

Revelation Biosciences, Inc. reported a net loss of $3.3 million for the second quarter of 2026, compared to a loss of $2.4 million in the same period of the previous year. For the first half of 2026, the company recorded a net loss of $6.3 million, up from $4.5 million in the first half of 2025. The increase in losses is attributed to higher operating expenses, which rose to $3.7 million in the second quarter of 2026 from $2.5 million in the prior year, driven primarily by increased research and development costs associated with its product candidates, GEM-AKI and GEM-CKD.

Operating expenses for the first half of 2026 totaled $6.8 million, a significant increase from $4.6 million in the same period of 2025. Research and development expenses alone increased to $3.3 million from $2.2 million, reflecting ongoing investments in clinical development and related activities. General and administrative expenses also rose to $3.5 million from $2.4 million, largely due to increased personnel costs and professional fees. The company has not generated any revenue to date and does not expect to do so until it successfully completes product development and obtains regulatory approval, which it anticipates will take several years.

In terms of strategic developments, Revelation Biosciences executed a Class I Warrant Inducement in January 2026, resulting in net proceeds of approximately $6.7 million from the exercise of warrants. This followed a public offering in May 2025 that raised $3.4 million. The company also adopted a stockholder rights plan in July 2026, aimed at protecting shareholder interests and preventing hostile takeovers. This plan includes the issuance of preferred stock purchase rights to existing shareholders, which will become exercisable if any individual or group acquires 10% or more of the company's common stock without board approval.

As of June 30, 2026, Revelation Biosciences had cash and cash equivalents of $11.5 million, which the company indicates may not be sufficient to sustain operations for the next year without additional funding. The company has an accumulated deficit of $55.8 million and plans to seek further capital through public or private equity or debt financing. However, it acknowledges the uncertainty surrounding its ability to secure such financing on favorable terms, which could impact its ongoing research and development efforts.

Looking ahead, Revelation Biosciences expects to continue incurring significant operating losses as it advances its product candidates through clinical trials and seeks regulatory approvals. The company remains focused on its development pipeline, which includes therapies for acute and chronic kidney diseases, while also navigating the challenges of funding and operational sustainability in the competitive biopharmaceutical landscape.